glp1medication.guide

access

GLP-1 Access in the United States: FDA Approvals, Coverage and Cash Prices

What this page establishes

  • The FDA approved Foundayo (orforglipron) on April 1, 2026 for adults with obesity, or with overweight and at least one weight-related comorbid condition, to reduce excess body weight and maintain the reduction long term.
  • Novo Nordisk announced on December 22, 2025 that the FDA approved the Wegovy pill (oral semaglutide, up to 25 mg daily, 1.5 mg starting dose) for weight reduction and for reducing major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight.
  • The Wegovy label lists a cardiovascular risk-reduction indication and weight indications for adults and for patients 12 and older with obesity; Zepbound is labeled for weight reduction and for moderate to severe obstructive sleep apnea in adults with obesity.
  • Ozempic injection is labeled for glycemic control in adults with type 2 diabetes, for reducing major adverse cardiovascular events in type 2 diabetes with established cardiovascular disease, and for reducing risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in type 2 diabetes with chronic kidney disease.

Quick answers

  • Is there a Wegovy or Zepbound coupon?

    The official routes are the manufacturers' self-pay programmes, NovoCare for Wegovy and LillyDirect for Zepbound and Foundayo, and the TrumpRx coupons.

    Read the full answer

    All need a prescription, are for people paying cash, and do not count toward an insurance deductible. Prices are in the table above.

  • How much does Zepbound cost without insurance?

    TrumpRx lists $299 a month. LillyDirect vials are reported at $299 to $449 a month depending on dose.

    Read the full answer

    The list price is $1,087.

  • If the FDA approved a GLP-1 for weight loss, will my insurance pay for it?

    Not necessarily. FDA approval means the drug may be marketed for that use. Coverage is decided by your plan.

    Read the full answer

    KFF's 2026 survey found 18% of firms with 200 or more workers cover these drugs for weight loss, and 40% of those that do require a lifestyle program or counseling. Check your plan's formulary and prior authorization rules.

Nine GLP-1 brands hold an FDA approval, and that approval is the same for every American. Coverage is not. A label that says a drug treats obesity does not oblige a commercial insurer to pay for it, and federal law has stopped Medicare from covering drugs used for weight loss. What a person pays depends on the indication written on the prescription, the plan behind the insurance card, and increasingly on a cash price set by the manufacturer. This page sets out each layer with its source and the date it was read. Prices and programs here were checked in November 2026 and several of them have changed within the past year.

Which brands the FDA has approved, and for what

All nine brands in this site's country table are FDA approved: Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity and Foundayo. The approval references are NDA209637 (Ozempic), NDA215256 (Wegovy), NDA213051 (Rybelsus), NDA215866 (Mounjaro), NDA217806 (Zepbound), NDA206321 (Saxenda), NDA022341 (Victoza), BLA125469 (Trulicity) and NDA220934 (Foundayo). Indications below were read from the FDA label text served by openFDA in November 2026.

Ozempic, Mounjaro, Rybelsus, Victoza and Trulicity are labeled for type 2 diabetes. Ozempic injection also carries labeled uses to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Mounjaro is labeled for glycemic control in adults and in pediatric patients 10 years and older with type 2 diabetes.

Wegovy, Zepbound, Saxenda and Foundayo are labeled for weight. Wegovy is indicated to reduce excess body weight and maintain the reduction in adults and in patients 12 and older with obesity, and in adults with overweight and at least one weight-related condition. It also carries an indication to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. Zepbound is labeled for weight reduction and for moderate to severe obstructive sleep apnea in adults with obesity. Saxenda is labeled for chronic weight management in adults and in patients 12 and older who weigh more than 60 kg and have obesity.

Two newer products are pills for weight. The FDA approved the Wegovy pill (oral semaglutide, up to 25 mg a day) on December 22, 2025, according to Novo Nordisk, with a 1.5 mg starting dose. The FDA approved Foundayo (orforglipron) on April 1, 2026, to reduce excess body weight and maintain the reduction in adults with obesity, or with overweight and at least one weight-related condition, under its National Priority Voucher pilot, which the agency says made it the fastest new molecular entity approval since 2002.

Approved is not the same as covered The FDA label sets what a company may promote. It does not set what an insurer must pay for. The same molecule is sold as Ozempic (diabetes) and Wegovy (weight), and that brand choice is what most coverage rules key on.

Commercial insurance: the obesity indication is often excluded

Most Americans under 65 get coverage through an employer. Whether that plan pays for a GLP-1 prescribed for weight loss is the employer's choice, and most large employers have chosen no. KFF's 2026 Employer Health Benefits Survey, published October 22, 2026, found that 18% of firms with 200 or more workers cover GLP-1 drugs when used primarily for weight loss, against 19% the year before. The share rises with size: 16% of firms with 200 to 999 workers, 29% of firms with 1,000 to 4,999 workers and 33% of firms with 5,000 or more.

Where plans do cover weight-loss use, conditions are normal. KFF reports that 40% of those firms, including 59% of the largest, require enrollees to meet with a dietitian, case manager or therapist, or to join a lifestyle program, up from 34% the year before. The survey figure quoted here is the lifestyle requirement. It is not a count of prior authorization or BMI rules, which this page did not measure.

Diabetes is the easier path. A prescription for Ozempic, Mounjaro, Trulicity or Rybelsus for type 2 diabetes is a diabetes indication, which plans treat separately from weight loss. This page did not measure formulary or prior authorization rules for it. A person with both diabetes and obesity is therefore covered or not depending on which diagnosis and which brand the prescriber writes, not on the person's full history. This page does not say which one a prescriber should choose.

Medicare: a statutory exclusion, two exceptions and a temporary Bridge

Medicare Part D has a statutory exclusion for drugs used for weight loss, and KFF summarizes it plainly: Medicare has been prohibited by law from covering medications when used specifically for weight loss. Part D plans may cover a GLP-1 for another FDA-approved, medically accepted indication. CMS confirms two that matter here: Wegovy to reduce major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. Both continue under ordinary Part D, outside the Bridge. Diabetes brands are covered for diabetes.

The change in effect now is a demonstration, not a change to the law. The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027. CMS extended it from its original shorter window because the BALANCE Model for Part D, planned to start in January 2027, has been delayed, and KFF describes that delay as indefinite. Under the Bridge, eligible Part D enrollees pay a $50 copay per one-month supply. The copay does not count toward the Part D deductible or the true out-of-pocket limit, and Part D plan sponsors do not carry risk or have to opt in. Covered products are Foundayo, Wegovy (injection or tablet) and the Zepbound KwikPen only, not Zepbound vials.

Eligibility is narrower than the label. Medicare.gov lists adults 18 and older with Part D who have a BMI of 35 or more, or a BMI of 30 to 34.9 plus heart failure with preserved ejection fraction, uncontrolled high blood pressure or stage 3a or worse chronic kidney disease, or a BMI of 27 to 29.9 plus prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. People who already get a GLP-1 through Part D, or who have type 2 diabetes, moderate to severe sleep apnea or fatty liver disease, are not eligible for the Bridge. The Bridge ends on December 31, 2027 and what follows has not been announced in any source this page opened.

What is law and what is a pilot The exclusion of weight-loss drugs from Part D is federal law and is unchanged. The $50 Bridge is a time-limited CMS demonstration that runs outside Part D. Do not read it as Medicare covering obesity drugs.

Medicaid: each state decides

States must cover nearly all FDA-approved drugs in Medicaid, but a long-standing statutory exception lets them choose whether to cover weight-loss drugs. KFF counted 13 state Medicaid programs covering GLP-1 drugs for obesity under fee-for-service as of January 2026, in an analysis published January 16, 2026. An October 2025 KFF survey had found 16. California, New Hampshire, Pennsylvania and South Carolina dropped coverage in between, and North Carolina ended coverage in October 2025 and restored it in December 2025. KFF ties the pullbacks to state budget pressure.

The federal BALANCE Model is designed to widen this for Medicaid. Its Medicaid track runs from May 1, 2026 through December 31, 2031, with states joining by signing an agreement with CMS and then adopting supplemental rebate agreements with participating manufacturers. KFF listed July 31, 2026 as the state participation deadline. Which states have joined was not confirmed in the sources this page opened, so no count is given. Anyone relying on Medicaid should check their own state's preferred drug list, since diabetes use is covered and weight-loss use depends on the state.

Cash prices at a glance, November 2026

Monthly self-pay prices from the manufacturers' own programmes and TrumpRx, all with a prescription and none counting toward an insurance deductible. Prices rise with dose, so the lowest figure is a starting price, not the cost of a full course. LillyDirect figures are from press reports because Lilly's pages could not be opened directly; check LillyDirect before relying on them.

MedicineWhereMonthly cash priceList price
Wegovy pillNovoCare$149 (1.5 mg), $199 (4 mg), $299 (9 and 25 mg)n/a
Wegovy penNovoCare$349 (1 to 2.4 mg), $399 (7.2 mg); $199 intro for the first two fills, new patients, to 31 Dec 2026$1,349
Wegovy penTrumpRx$199 headline$1,349
OzempicTrumpRx$199 headline$1,028
Zepbound vialsLillyDirect (reported)$299 (2.5 mg), $349 (5 mg), $449 (7.5 to 15 mg)$1,087
ZepboundTrumpRx$299 headline$1,087
FoundayoLillyDirect (reported)$149 (0.8 mg), $199 (2.5 mg), $299 to $349 (higher doses)n/a

Manufacturer cash-pay programs and TrumpRx

Both manufacturers now sell directly to people paying cash, outside insurance. Novo Nordisk's NovoCare page, read in November 2026, lists the Wegovy pill at $149 a month for the 1.5 mg dose, $199 for 4 mg and $299 for 9 mg and 25 mg. The Wegovy pen is $349 a month at the 1 mg, 1.7 mg and 2.4 mg doses and $399 for the 7.2 mg dose, with a $199 introductory price for two monthly fills of the 0.25 mg and 0.5 mg doses for new patients through December 31, 2026. NovoCare says these cash payments do not count toward insurance deductibles or limits.

TrumpRx, the federal website launched on February 6, 2026, lists Wegovy pills at $149 a month, the Wegovy pen at $199, Ozempic at $199 and Zepbound at $299, against list prices of $1,349 for Wegovy, $1,028 for Ozempic and $1,087 for Zepbound. KFF's February 2026 analysis explains how it works: for most drugs it provides coupons redeemed at pharmacies, only a handful of drugs can be bought through linked pharmacies, the prices apply only to cash-paying patients, a prescription is always required, and the amounts do not count toward deductibles. The TrumpRx page shows a single headline price, while NovoCare shows the price rising with dose, so a $149 or $199 headline is a starting price and not necessarily what a full course costs.

Eli Lilly also sells Zepbound and Foundayo through LillyDirect. Lilly's pages could not be opened by this page's research tooling, so LillyDirect vial and Foundayo prices are not stated here. The only Lilly-related price confirmed from a primary page is TrumpRx's $299 monthly figure for Zepbound.

Compounded semaglutide and tirzepatide

During a shortage, US law lets pharmacies compound copies of a drug. The FDA ended that window in two steps. It declared the tirzepatide shortage resolved on December 19, 2024. State-licensed pharmacies (section 503A) had until February 18, 2025 and outsourcing facilities (section 503B) until March 19, 2025. It declared the semaglutide shortage resolved on February 21, 2025, with enforcement discretion ending April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities.

Those dates removed the shortage justification. The FDA's stated position is that outsourcing facilities cannot lawfully compound from bulk drug substances when approved drugs are available, unless there is a clear clinical need. On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, with public comment open through June 29, 2026. Whether that exclusion has been finalized was not confirmed in the sources this page opened.

The FDA's page on unapproved GLP-1 drugs, last updated October 1, 2026, reports that as of May 31, 2026 it held 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide, and notes that state-licensed pharmacies are not required to report to the agency, so these counts are probably low. It documents dosing errors, some requiring hospitalization, from patients measuring doses wrongly and from prescribers miscalculating them, and reports of patients receiving doses above the approved label. This page does not recommend or rank any compounder.

The evidence, one row per claim

ClaimTierSource
The FDA approved Foundayo (orforglipron) on April 1, 2026 for adults with obesity, or with overweight and at least one weight-related comorbid condition, to reduce excess body weight and maintain the reduction long term.establishedFDA press announcement, April 1, 2026
Novo Nordisk announced on December 22, 2025 that the FDA approved the Wegovy pill (oral semaglutide, up to 25 mg daily, 1.5 mg starting dose) for weight reduction and for reducing major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight.establishedNovo Nordisk US press release
The Wegovy label lists a cardiovascular risk-reduction indication and weight indications for adults and for patients 12 and older with obesity; Zepbound is labeled for weight reduction and for moderate to severe obstructive sleep apnea in adults with obesity.establishedFDA Structured Product Label via openFDA (Wegovy, NDA215256); Zepbound at https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ZEPBOUND%22&limit=2
Ozempic injection is labeled for glycemic control in adults with type 2 diabetes, for reducing major adverse cardiovascular events in type 2 diabetes with established cardiovascular disease, and for reducing risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in type 2 diabetes with chronic kidney disease.establishedFDA Structured Product Label via openFDA (Ozempic, NDA209637)
Saxenda is labeled for chronic weight management in adults with overweight and a weight-related condition and in patients 12 and older weighing more than 60 kg with obesity; Victoza is labeled for type 2 diabetes in patients 10 and older.establishedFDA Structured Product Label via openFDA (Saxenda; Victoza at https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22VICTOZA%22&limit=1)
KFF's 2026 Employer Health Benefits Survey (October 22, 2026) found 18% of firms with 200 or more workers cover GLP-1 drugs for weight loss (16% of firms with 200 to 999 workers, 29% of firms with 1,000 to 4,999, 33% of firms with 5,000 or more), and 40% of covering firms require a lifestyle program or counseling.establishedKFF 2026 Employer Health Benefits Survey
Medicare has been prohibited by law from covering medications when used specifically for weight loss.establishedKFF, What to Know About the BALANCE Model and the Medicare GLP-1 Bridge, May 11, 2026
Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, and Wegovy to reduce major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, remain covered through Part D rather than the Bridge.establishedCMS, Medicare GLP-1 Bridge: Information for Part D Plans
The Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027, with a $50 copay that does not count toward TrOOP and no Part D deductible, and Part D sponsors carry no risk and need not opt in.establishedCMS, Medicare GLP-1 Bridge
The Bridge covers all formulations of Foundayo and Wegovy and only the KwikPen formulation of Zepbound; the BALANCE Model Part D start planned for January 2027 is indefinitely delayed.establishedKFF, May 11, 2026
Bridge eligibility: age 18 or older with Part D and BMI of 35 or more, or BMI 30 to 34.9 plus heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a or worse CKD, or BMI 27 to 29.9 plus prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease; excludes people with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease.establishedMedicare.gov, Medicare GLP-1 Bridge
Thirteen state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026, down from 16 in October 2025; California, New Hampshire, Pennsylvania and South Carolina ended coverage.establishedKFF, Medicaid Coverage of and Spending on GLP-1s, January 16, 2026
The BALANCE Model Medicaid track runs May 1, 2026 through December 31, 2031, with a state participation deadline of July 31, 2026.establishedKFF, May 11, 2026
NovoCare self-pay Wegovy prices in November 2026: pill $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg); pen $349 (1 mg, 1.7 mg, 2.4 mg), $399 (7.2 mg); $199 introductory price for two fills of 0.25 mg and 0.5 mg for new patients through December 31, 2026.establishedNovoCare Pharmacy, Wegovy pricing page
TrumpRx lists Wegovy pill $149 a month, Wegovy pen $199, Ozempic $199 and Zepbound $299, against list prices of $1,349, $1,349, $1,028 and $1,087.establishedTrumpRx.gov, read November 2026
TrumpRx launched February 6, 2026, mostly provides manufacturer coupons, applies only to cash-paying patients, requires a prescription, and its payments do not count toward deductibles or out-of-pocket maximums.establishedKFF, TrumpRx: What's the Value for Customers?, February 24, 2026
The FDA declared the tirzepatide shortage resolved December 19, 2024 (503A discretion ended February 18, 2025; 503B ended March 19, 2025) and the semaglutide shortage resolved February 21, 2025 (503A ended April 22, 2025; 503B ended May 22, 2025).establishedFDA, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, with comments open through June 29, 2026.establishedFDA press announcement, April 30, 2026
As of May 31, 2026 the FDA held 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, likely underreported, including dosing-error cases requiring hospitalization.establishedFDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, updated October 1, 2026
LillyDirect self-pay Zepbound vials are reported at $299 (2.5 mg), $349 (5 mg) and $449 (7.5 to 15 mg) a month, and Foundayo from $149 (0.8 mg) to $299-$349 at higher doses.reportedFierce Pharma, LillyDirect self-pay pricing
IRS Publication 502 allows amounts paid to lose weight as medical expenses when the weight loss treats a specific disease diagnosed by a physician, such as obesity, hypertension or heart disease.establishedIRS Publication 502 (2025)
The Wegovy savings card excludes patients enrolled in federal or state health care programs with prescription drug coverage (Medicare, Medicaid, VA, DOD, TRICARE); FEHB, ACA exchange and state employee plans are not treated as government programs for this offer.establishedNovoCare, Wegovy savings card terms
FDA states that in most circumstances it is illegal for individuals to import drugs into the US for personal use, and lists warning signs of unsafe online pharmacies in its BeSafeRx guidance.establishedFDA, Personal Importation

Questions people ask

Does Medicare cover Wegovy or Zepbound?

Not for weight loss under ordinary Part D, because federal law excludes it. Part D can cover Wegovy to reduce cardiovascular events in people with established cardiovascular disease and obesity or overweight, and Zepbound for moderate to severe obstructive sleep apnea. From July 1, 2026 through December 31, 2027 a separate CMS demonstration, the Medicare GLP-1 Bridge, lets eligible Part D enrollees pay $50 a month for Wegovy, the Zepbound KwikPen or Foundayo.

Does Medicaid pay for GLP-1 drugs for obesity?

It depends on your state. Weight-loss coverage is optional for states, and KFF counted 13 state programs covering it under fee-for-service in January 2026. Coverage for diabetes is far more widespread. A federal model called BALANCE is meant to expand Medicaid coverage, but which states joined was not confirmed in the sources used here.

Is the TrumpRx price what I will pay each month?

Only if you pay cash, have a prescription and the starting price applies to your dose. Per KFF, TrumpRx prices apply only to cash-paying patients and do not count toward insurance deductibles. NovoCare lists Wegovy pill prices that rise from $149 to $299 as the dose goes up, so a headline figure may cover only the first doses.

Is compounded semaglutide or tirzepatide still legal?

The FDA ended the shortage-based permission in 2025, with the last enforcement discretion date for either drug on May 22, 2025. Compounding from bulk substances is lawful only where there is a clear clinical need, and the FDA proposed on April 30, 2026 to exclude these drugs from the 503B bulks list. The FDA reports adverse events and dosing errors with compounded products. This page does not recommend any source.

Can I get Ozempic covered for weight loss if I do not have diabetes?

Ozempic is labeled for type 2 diabetes, so most plans cover it only for that use. Wegovy contains the same molecule and carries the weight indications. Which one a prescriber writes is a medical decision for you and your prescriber, and your plan's rules follow the indication on the prescription.

Can I pay for Wegovy or Zepbound with an HSA or FSA?

Usually yes, when it is prescribed to treat a diagnosed condition. IRS Publication 502 lets you count amounts paid to lose weight as a medical expense if it treats a specific disease diagnosed by a physician, such as obesity, hypertension or heart disease, and prescribed drugs are medical expenses. Your HSA or FSA administrator may ask for a letter of medical necessity, so check their rules first.

Can I use a manufacturer savings card if I have Medicare or Medicaid?

No. The Wegovy savings card terms exclude anyone enrolled in a federal or state health care program with drug coverage, including Medicare, Medicaid, Tricare and VA. That follows from the federal anti-kickback rules. The terms also say federal employee (FEHB), Affordable Care Act exchange and state employee plans do not count as government programs for this purpose.

Is it legal to buy Wegovy or Ozempic from another country or online without a US prescription?

In most cases, no. The FDA says it is usually illegal to import prescription drugs for personal use, and it cannot vouch for medicines bought outside the US supply chain. Its BeSafeRx guidance lists warning signs of unsafe online pharmacies: selling without a prescription, prices that look too good to be true, shipping from abroad and no US state pharmacy licence.

Sources

  1. FDA press announcement, April 1, 2026
  2. Novo Nordisk US press release
  3. FDA Structured Product Label via openFDA (Wegovy, NDA215256); Zepbound at https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ZEPBOUND%22&limit=2
  4. FDA Structured Product Label via openFDA (Ozempic, NDA209637)
  5. FDA Structured Product Label via openFDA (Saxenda; Victoza at https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22VICTOZA%22&limit=1)
  6. KFF 2026 Employer Health Benefits Survey
  7. KFF, What to Know About the BALANCE Model and the Medicare GLP-1 Bridge, May 11, 2026
  8. CMS, Medicare GLP-1 Bridge: Information for Part D Plans
  9. CMS, Medicare GLP-1 Bridge
  10. Medicare.gov, Medicare GLP-1 Bridge
  11. KFF, Medicaid Coverage of and Spending on GLP-1s, January 16, 2026
  12. NovoCare Pharmacy, Wegovy pricing page
  13. TrumpRx.gov, read November 2026
  14. KFF, TrumpRx: What's the Value for Customers?, February 24, 2026
  15. FDA, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
  16. FDA press announcement, April 30, 2026
  17. FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, updated October 1, 2026
  18. Fierce Pharma, LillyDirect self-pay pricing
  19. IRS Publication 502 (2025)
  20. NovoCare, Wegovy savings card terms
  21. FDA, Personal Importation

Where this comes from

Every number on this page traces to a named source. There are 23 sourced claims below the fold, each with the document it came from.

Sources consulted: FDA press announcement, Novo Nordisk US press release, FDA Structured Product Label via openFDA, KFF 2026 Employer Health Benefits Survey, KFF and 8 more.

Medical review pending

Sources last read 2026-08-23.

Mark glp1medication.guide as a preferred source Our GLP-1 guides show up more often, with a Preferred badge

Keep reading

Medical review pending. Not medical advice, not a prescription, and not a substitute for a clinician who knows your history. Doses named here are label schedules or doses used in named trials, never a recommendation to you.